IL-33 (Interleukin-33): Complete Research Profile — The Nuclear Alarmin, ST2/IL-1RAcP Signaling, Type 2 Inflammation, and Anti-IL-33 Biologic Research (2026)

Overview

IL-33 is a pleiotropic cytokine of the IL-1 superfamily that occupies a unique position at the interface of tissue surveillance and innate immune activation. First characterized as an IL-1 family cytokine in 2005 by Schmitz and colleagues, IL-33 functions as both an intranuclear chromatin-binding protein and a secreted alarmin — one of only a handful of cytokines with dual intracellular and extracellular roles.

Unlike most cytokines that are synthesized and secreted in response to inflammatory signals, IL-33 is constitutively expressed and stored in the nucleus of structural and stromal cells — particularly epithelial cells, endothelial cells, fibroblasts, and smooth muscle cells — at sites of barrier function throughout the body. This nuclear residency is not merely passive storage: full-length IL-33 actively participates in chromatin organization and transcriptional regulation through its N-terminal chromatin-binding domain. Upon mechanical damage, cellular necrosis, or pathogen encounter, IL-33 is rapidly released — without secretory vesicle trafficking — to alert adjacent and recruited immune cells to tissue injury.

This "alarmin" biology distinguishes IL-33 from canonically secreted cytokines and makes it a first-responder signal in barrier tissue immunity. Its downstream receptor, ST2 (also known as IL-1RL1), is constitutively expressed on key innate and adaptive immune cells, particularly group 2 innate lymphoid cells (ILC2s), mast cells, eosinophils, and T helper 2 (Th2) cells — positioning IL-33 as a master initiator of type 2 immune responses.

> Research Use Only (RUO) Notice: All information presented in this article is for laboratory research purposes only. IL-33 and all reagents described are not approved for clinical, veterinary, diagnostic, or any in-human or in-animal use.

---

Gene, Protein Structure, and Isoforms

The human IL33 gene is located on chromosome 9p24.1 and encodes a 270-amino-acid precursor protein (full-length IL-33, IL-33FL) with a molecular weight of approximately 30 kDa. The gene comprises eight exons, and alternative splicing generates multiple tissue-specific isoforms, though the full-length form predominates in most structural cell populations.

IL-33 protein contains two functionally distinct domains:

N-Terminal Nuclear Localization and Chromatin-Binding Domain (Residues 1–109)

This domain contains a nuclear localization sequence and a homeodomain-like structure that mediates binding to histone H2A/H2B dimers and chromatin. It is responsible for the nuclear sequestration of IL-33 under homeostatic conditions, and evidence suggests it participates in transcriptional repression at heterochromatin boundaries. Importantly, this domain has no known receptor-binding activity and does not contribute to ST2 engagement.

C-Terminal IL-1-Like Cytokine Domain (Residues 112–270)

The C-terminal domain adopts the characteristic β-trefoil fold shared by all IL-1 family members and is exclusively responsible for ST2 receptor engagement. Unlike IL-1β and IL-18, full-length IL-33 does not require caspase-1 processing to achieve biological activity — even uncleaved IL-33 can bind ST2 and activate downstream signaling, though at substantially reduced potency relative to processed mature forms.

IL-33 lacks a classical signal peptide and cannot enter the endoplasmic reticulum secretory pathway, explaining why its release is obligatorily coupled to cell damage rather than conventional vesicle exocytosis.

---

Proteolytic Processing: From Full-Length to Hyperactive Forms

A defining feature of IL-33 biology is that its extracellular potency is dramatically regulated by proteolytic processing. Four distinct processing outcomes are well-characterized:

Full-Length IL-33 (aa 1–270)

Released from necrotic cells, full-length IL-33 retains moderate ST2-activating activity and represents the initial "first wave" alarmin signal. It is the predominant form measured in tissue homogenates and cell culture supernatants when cells die by necrosis rather than apoptosis.

N-Terminally Processed Mature Forms (Superagonists)

Serine proteases from inflammatory cells dramatically enhance IL-33 potency through N-terminal truncation. The best-characterized enzymes include:

• •Neutrophil elastase (NE), cathepsin G, and proteinase 3: Neutrophil-derived serine proteases cleave IL-33 at multiple sites within the N-terminal domain to generate processed forms (approximately residues 99–270 or shorter) that are up to 30-fold more potent than full-length IL-33 on ILC2s (Cayrol et al., PNAS 2014; Lefrançais et al., PMC 2012).
• •Mast cell tryptase and chymase: Generate equivalent superagonist forms and create an important positive feed-forward amplification loop during mast cell activation, as released mast cell proteases further process accumulated extracellular IL-33.

This amplification means that during neutrophilic or mast cell-rich inflammatory infiltration, the initial necrotic IL-33 signal is progressively converted to increasingly potent processed forms.

Caspase-Mediated Inactivation

During apoptotic cell death, caspase-3 and caspase-7 cleave IL-33 at residue Asp178 within the IL-1-like cytokine domain, rendering it biologically inactive. This inactivation is thought to prevent inappropriate immune activation during programmed cell death — a key molecular distinction between apoptosis (immune-silent) and necrosis (alarmin-releasing). The contrast between caspase-mediated inactivation of IL-33 during apoptosis vs. protease-mediated superactivation during inflammation is a central paradigm in alarmin research (Cayrol & Girard, Curr Opin Immunol 2014).

Oxidative Inactivation

IL-33 contains conserved cysteines (C208, C232) that can form an intramolecular disulfide bond under oxidizing conditions. This disulfide blocks ST2 binding and inactivates the cytokine. Oxidative inactivation by ROS in inflamed tissues provides a self-limiting mechanism for the IL-33 signal duration. This has critical practical implications: recombinant IL-33 research reagents rapidly lose activity upon oxidation and must be stored and handled under reducing conditions.

---

ST2 Receptor Complex and Signal Transduction

IL-33 signals through a heterodimeric receptor complex composed of the primary binding subunit ST2 (IL-1RL1, encoded by IL1RL1) and the co-receptor IL-1 receptor accessory protein (IL-1RAcP, IL-1R3). Both subunits are type I transmembrane proteins with extracellular immunoglobulin-like domains and intracellular Toll/IL-1R (TIR) domains.

ST2 Isoforms: Membrane ST2 vs. Soluble sST2

The IL1RL1 locus generates two functionally opposed isoforms through alternative promoter usage:

• •Transmembrane ST2 (ST2L): The full-length receptor mediating IL-33 signaling, constitutively expressed on ILC2s, mast cells, eosinophils, Th2 cells, basophils, and regulatory T cells.
• •Soluble ST2 (sST2): A secreted decoy receptor that lacks transmembrane and intracellular domains. sST2 competitively sequesters IL-33 in plasma and tissues, preventing engagement with ST2L. Elevated plasma sST2 is a validated biomarker in heart failure and an endogenous negative regulator of the IL-33 axis. The ratio of sST2 to IL-33 critically determines the magnitude of receptor-level signaling.

Intracellular Signal Cascade: MyD88 → NF-κB and MAPK

Upon IL-33 binding, ST2L and IL-1RAcP heterodimerize and their TIR domains recruit the central adaptor MyD88. The canonical IL-1 family signaling cascade follows:

1. MyD88 → IRAK4/IRAK1 → TRAF6: MyD88 bridges the receptor complex to IRAK4, which phosphorylates and activates IRAK1. Active IRAK1 ubiquitinates TRAF6 with K63-linked polyubiquitin chains.

2. TRAF6 → TAK1 → IKK → NF-κB: The K63 polyubiquitin scaffold on TRAF6 activates TAK1 (MAP3K7), which phosphorylates the IκB kinase (IKK) complex. IKKβ phosphorylates IκBα, triggering proteasomal degradation and nuclear translocation of canonical NF-κB (p65/p50) to drive cytokine gene expression.

3. TAK1 → MKKs → p38/JNK/ERK MAPK: TAK1 also activates p38 (via MKK3/6), JNK (via MKK4/7), and ERK1/2 (via MEK1/2). These MAPK cascades activate AP-1 transcription factors and contribute to the full transcriptional response.

The integrated NF-κB and MAPK output drives cell-type-specific programs: rapid IL-5 and IL-13 secretion in ILC2s; degranulation and cytokine production in mast cells; enhanced survival and effector function in eosinophils (IL-33/ST2 axis review, PMC 2025).

---

Key Responsive Cell Types

Group 2 Innate Lymphoid Cells (ILC2s) — Primary Effectors

ILC2s (Lin⁻CD127⁺CRTH2⁺CD161⁺) are the primary and most potent effectors downstream of IL-33, expressing the highest ST2 surface density of any immune cell. IL-33 alone is sufficient to drive rapid ILC2 activation and secretion of IL-5 (eosinophil mobilization) and IL-13 (mucus hypersecretion, airway smooth muscle contraction). IL-33 acts synergistically with TSLP and IL-25 (IL-17E) to amplify ILC2 responses. ILC2 activation by IL-33 is the earliest innate event in type 2 inflammatory cascades and precedes adaptive Th2 responses by 24–72 hours, making it the critical initiating node in allergen challenge research models.

Mast Cells

Mast cells express ST2 constitutively and respond to IL-33 with enhanced cytokine production (IL-4, IL-5, IL-6, IL-13, TNF-α) and potentiated IgE-dependent degranulation. The positive feed-forward loop — mast cell proteases processing IL-33 to hyperactive forms, which further activate mast cells — is a key amplification mechanism in early allergic responses.

Eosinophils

IL-33 directly promotes eosinophil survival through NF-κB-driven anti-apoptotic gene expression, enhances adhesion molecule expression (CD11b, L-selectin), and augments degranulation responses. IL-33 upregulates ST2 expression on eosinophils in an autocrine fashion, increasing their responsiveness to subsequent IL-33 stimulation.

T Helper 2 (Th2) Cells

Effector Th2 cells express ST2, and IL-33 acts as a direct co-stimulatory signal amplifying their IL-4, IL-5, and IL-13 production. This adaptive arm of the IL-33 response is particularly relevant in chronic allergic disease and helminth infection models where the innate ILC2 burst has transitioned to adaptive Th2 dominance.

Regulatory T Cells (Tregs)

Tissue-resident ST2+ Tregs in barrier organs (lung, skin, intestine) respond to IL-33 with expansion and enhanced suppressive function. This dual biology — simultaneously driving type 2 effector responses and expanding tissue-regulatory Tregs — means IL-33 does not uniformly amplify inflammation but also recruits concurrent tissue-repair programs.

Cardiac Fibroblasts and Cardiomyocytes

An important non-immune function: cardiac fibroblasts constitutively express IL-33 and sST2. Mechanical stretch drives IL-33 release from fibroblasts, which signals through ST2 on cardiomyocytes to activate cardioprotective PI3K/Akt and ERK1/2 pathways, counterbalancing pathological hypertrophic remodeling. This cardioprotective axis explains why elevated sST2 (which decoys the protective IL-33 signal) is a strong prognostic marker in heart failure (IL-33 respiratory disease review, PMC 2024).

---

Biological Roles in Research Contexts

Type 2 Inflammation and Allergic Airway Models

IL-33 is one of three canonical epithelial alarmins (alongside TSLP and IL-25) and is the most extensively studied in airway inflammation. In murine models, intranasal IL-33 robustly drives airway eosinophilia, goblet cell hyperplasia, and ILC2 expansion within 24–72 hours — establishing it as the standard positive control for ILC2 activation assays. The IL33 gene is a major susceptibility locus for human asthma in GWAS studies, with SNPs in both IL33 and IL1RL1 (ST2) independently associated with asthma risk (IL-33 immunobiology review, PMC 2022).

Alternative splicing of IL-33 exons generates tissue-specific isoforms that differentially contribute to type 2 airway disease, a finding validated in human bronchial epithelial tissue biopsies.

Tissue Injury and Barrier Repair

Beyond allergic disease, IL-33 participates in tissue repair programs after mechanical damage, infection, or chemical injury. It promotes expansion of amphiregulin-producing ILC2s and ST2+ Tregs that facilitate epithelial regeneration. IL-33 knockout mice show delayed recovery from certain mucosal injuries, demonstrating a physiological role in the wound-healing response that is distinct from its pro-inflammatory alarmin function.

Cardiac Remodeling Research

The cardioprotective IL-33/ST2 axis is activated by biomechanical stretch in the pressure-overloaded heart, counterbalancing hypertrophy and fibrosis through PI3K/Akt activation. Loss of this pathway — modeled by ST2 knockout or sST2 overexpression — accelerates cardiac fibrosis. Recombinant IL-33 administration in rodent pressure-overload models reduces fibrosis and preserves cardiac function, establishing a rationale for studying IL-33/ST2 as a research target in remodeling biology.

Cancer Immunology

The role of IL-33 in cancer is context-dependent and bidirectional. In immunologically "hot" tumor microenvironments, IL-33 can activate NK cell and CD8+ T cell responses to promote tumor rejection. Conversely, in tumors with strong type 2 polarization (colorectal, pancreatic, breast), the IL-33/ST2/ILC2 axis promotes regulatory T cell accumulation and tumor-promoting macrophage polarization. Recent work from PMC 2025 (IL-33/ST2 review) documents how ST2 expression on tumor-associated macrophages drives M2 polarization and angiogenesis. This duality makes IL-33 a critical research target in cancer immunobiology that requires careful context-specific interpretation.

---

Research Applications and Laboratory Tools

Recombinant IL-33 as a Research Reagent

Recombinant human IL-33 is available in several forms optimized for different research applications:

• •Full-length rhIL-33 (aa 1–270): Used for broad cellular activation studies where moderate potency is appropriate, or for investigations of nuclear IL-33 biology.
• •Mature/processed rhIL-33 (aa 112–270 or aa 99–270): The C-terminal cytokine domain fragment with substantially higher specific activity on ST2-expressing cells. Preferred for ILC2 activation assays, mast cell stimulation protocols, and ST2-binding studies where maximal potency and signal-to-noise ratio are required.
• •Biotinylated or His-tagged IL-33: For receptor-binding studies, SPR kinetic measurements (K_D determination), and pull-down assays.

Critical handling note for researchers: Recombinant IL-33 is exquisitely sensitive to oxidative inactivation through C208–C232 disulfide formation. Research-grade IL-33 must be stored with 1–5 mM DTT (dithiothreitol) or 0.1–0.5 mM TCEP and validated for biological activity upon each use. Loss of ILC2-stimulating activity in stored IL-33 preparations lacking reducing agent is among the most common sources of experimental irreproducibility in type 2 innate immunity research.

ILC2 Isolation and Activation Protocols

IL-33 is the standard activating stimulus in ILC2 research. Lin⁻CD127⁺CRTH2⁺CD161⁺ ILC2s isolated from lung, peripheral blood, or intestine by FACS are routinely stimulated with:

• •IL-33 alone (5–50 ng/mL): drives IL-5 and IL-13 production within 24–48 hours
• •IL-33 + IL-25 + TSLP (combinatorial): maximally activates ILC2s and approximates in vivo allergen challenge conditions
• •IL-33 + PMA/ionomycin (for intracellular cytokine staining controls)

Anti-CD3/CD28 stimulation should be excluded from ILC2 activation assays to prevent T cell contamination artifacts.

ST2 Pathway Readouts

Phospho-flow cytometry or western blotting for p-IκBα, p-p38, p-JNK, and p-ERK1/2 provides direct, rapid readouts of IL-33/ST2 pathway activation. Reporter cell lines stably expressing human ST2 and IL-1RAcP with an NF-κB-luciferase or NF-κB-SEAP reporter offer high-throughput quantitative alternatives for IL-33 potency measurements and competitive inhibition studies.

Murine Airway Inflammation Models

Intranasal instillation of 0.5–1 μg recombinant IL-33 in C57BL/6 mice (3–5 consecutive daily doses) induces:

• •Bronchoalveolar lavage (BAL) eosinophilia (>40% eosinophils by day 5)
• •Goblet cell metaplasia (PAS staining)
• •Elevated BAL IL-5 and IL-13
• •Lung ILC2 expansion (>10-fold over baseline)

IL-33⁻/⁻ and ST2⁻/⁻ mice serve as negative controls in allergen challenge experiments to confirm pathway specificity.

sST2 ELISA as a Pharmacodynamic Biomarker

Plasma or serum sST2 is measurable by sandwich ELISA (several commercial kits validated for mouse and human). sST2 levels correlate inversely with functional IL-33 signaling magnitude — rising sST2 buffers IL-33 availability — and serve as a pharmacodynamic endpoint in pathway intervention studies.

---

Anti-IL-33 Biologics: Research Reference

Several monoclonal antibodies targeting the IL-33/ST2 axis have advanced through clinical development, and characterized variants are available as research-grade tools:

These biologics are described for research context only. They are not approved for clinical use. Anti-IL-33 and anti-ST2 antibodies based on these published sequences are available from research antibody suppliers for in vitro pathway inhibition and in vivo murine model experiments.

---

Relationship to Other Cytokines

IL-33 functions within a broader cytokine network, and its biology is best understood in the context of key interacting pathways:

• •IL-1β: The canonical IL-1 family member sharing IL-1RAcP as co-receptor and converging on MyD88/IRAK4/NF-κB. Unlike IL-33, IL-1β requires caspase-1 cleavage for activation (see our IL-1β research profile).

• •IL-4 and IL-13: The Th2 effector cytokines most directly downstream of IL-33/ILC2 activation. The IL-33 → ILC2 → IL-13 → goblet cell axis is the prototypical epithelial-to-effector cascade in type 2 inflammation (see our IL-4/IL-13 research profile).

• •TSLP: The other major epithelial alarmin acting through IL-7Rα/TSLPR. TSLP and IL-33 have synergistic effects on ILC2 and Th2 activation and are co-expressed at epithelial barrier sites. Tezepelumab (anti-TSLP) blocks upstream of both IL-33 and IL-25 amplification pathways.

• •IFN-γ: Antagonistic to IL-33 function — IFN-γ suppresses ST2 expression and ILC2 activity, defining the type 1/type 2 immune balance. See our IFN-γ research profile.

---

Research Tools Summary

---

Conclusion

IL-33 represents a mechanistically rich convergence point between tissue surveillance, innate immunity, and adaptive type 2 immune responses. Its alarmin biology — constitutive nuclear expression, necrosis-gated release, protease-mediated superactivation, and apoptotic silencing — distinguishes it from conventionally secreted cytokines and demands careful experimental design. The ST2/IL-1RAcP → MyD88 → NF-κB/MAPK signaling axis is among the best-characterized in IL-1 family biology, and the soluble decoy receptor sST2 provides a built-in endogenous modulatory tool researchers can leverage for pathway manipulation.

The translation of IL-33 biology into clinical biologic development — with itepekimab, tozorakimab, and astegolimab reaching Phase 2/3 stages — validates the mechanistic framework developed in laboratory research models. For researchers working with ILC2 biology, mucosal immunity, cardiac remodeling, allergic disease models, or cancer tumor microenvironments, IL-33 is an indispensable research component with well-defined tools, validated models, and a growing body of mechanistic literature.

---

All information is provided for Research Use Only (RUO). IL-33, anti-IL-33 biologics, and all reagents described herein are intended solely for laboratory investigation. They are not approved for clinical, veterinary, diagnostic, or any in-human or in-animal application.